pharmaphorum February 14, 2024
Phil Taylor

Ipsen has won FDA approval for first-line use of its pancreatic cancer therapy Onivyde, saying it is now part of a potential new “standard-of-care” for patients.

Onivyde (pegylated liposomal irinotecan) given as part of the NALIRIFOX regimen alongside oxaliplatin, 5-fluorouracil (5-FU) and leucovorin can now be used to treat previously untreated metastatic pancreatic adenocarcinoma (mPDAC), according to the US regulator. It is the first new treatment for this patient group in more than a decade.

In the phase 3 NAPOLI-3 study, the Onivyde regimen showed an improvement in overall survival (OS) and progression-free survival (PFS) when compared to the standard first-line treatment regimen of Bristol-Myers Squibb’s Abraxane (nab-paclitaxel) plus gemcitabine.

There was a statistically significant improvement in OS of 11.1...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Pharma Pulse 3/14/25: Navigating Internal Constraints and Uncertainty, Health Plan Support During Natural Disasters & more
New AI model can estimate a person's true biological age from five drops of blood
Spotiphy AI Tool Enhances Spatial Transcriptomics for Precision Medicine
Pharma Firms Mallinckrodt and Endo Agree to Merge in $6.7B Cash and Stock Deal
FDA Approves First Biosimilar to Omalizumab

Share This Article